Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,022 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Age and sex differences in presentation of symptoms among patients with acute coronary disease: the REACT Trial. Rapid Early Action for Coronary Treatment.
Goldberg R, Goff D, Cooper L, Luepker R, Zapka J, Bittner V, Osganian S, Lessard D, Cornell C, Meshack A, Mann C, Gilliland J, Feldman H. Goldberg R, et al. Among authors: feldman h. Coron Artery Dis. 2000 Jul;11(5):399-407. doi: 10.1097/00019501-200007000-00004. Coron Artery Dis. 2000. PMID: 10895406 Clinical Trial.
Post hoc analysis of ADAMANT, a phase 2 clinical trial of active tau immunotherapy with AADvac1 in patients with Alzheimer's disease, positive for plasma p-tau217.
Kovacech B, Cullen NC, Novak P, Hanes J, Kontsekova E, Katina S, Parrak V, Fresser M, Vanbrabant J, Feldman HH, Winblad B, Stoops E, Vanmechelen E, Zilka N. Kovacech B, et al. Among authors: feldman hh. Alzheimers Res Ther. 2024 Nov 23;16(1):254. doi: 10.1186/s13195-024-01620-7. Alzheimers Res Ther. 2024. PMID: 39580468 Free PMC article. Clinical Trial.
Alzheimer Disease as a Clinical-Biological Construct-An International Working Group Recommendation.
Dubois B, Villain N, Schneider L, Fox N, Campbell N, Galasko D, Kivipelto M, Jessen F, Hanseeuw B, Boada M, Barkhof F, Nordberg A, Froelich L, Waldemar G, Frederiksen KS, Padovani A, Planche V, Rowe C, Bejanin A, Ibanez A, Cappa S, Caramelli P, Nitrini R, Allegri R, Slachevsky A, de Souza LC, Bozoki A, Widera E, Blennow K, Ritchie C, Agronin M, Lopera F, Delano-Wood L, Bombois S, Levy R, Thambisetty M, Georges J, Jones DT, Lavretsky H, Schott J, Gatchel J, Swantek S, Newhouse P, Feldman HH, Frisoni GB. Dubois B, et al. Among authors: feldman hh. JAMA Neurol. 2024 Nov 1. doi: 10.1001/jamaneurol.2024.3770. Online ahead of print. JAMA Neurol. 2024. PMID: 39483064
Challenging Case: Family Navigation for Autism Spectrum Disorder.
Lin IY, Stahmer AC, Feinberg E, Feldman HM, Deras M, Augustyn M. Lin IY, et al. Among authors: feldman hm. J Dev Behav Pediatr. 2024 Oct 23. doi: 10.1097/DBP.0000000000001322. Online ahead of print. J Dev Behav Pediatr. 2024. PMID: 39446066
Varoglutamstat: Inhibiting Glutaminyl Cyclase as a Novel Target of Therapy in Early Alzheimer's Disease.
Feldman HH, Messer K, Qiu Y, Sabbagh M, Galasko D, Turner RS, Lopez O, Smith A, Durant J, Lupo JL, Revta C, Balasubramanian A, Kuehn-Wache K, Wassmann T, Schell-Mader S, Jacobs DM, Salmon DP, Léger G, DeMarco ML, Weber F; ADCS VIVA-MIND Study Group. Feldman HH, et al. J Alzheimers Dis. 2024;101(s1):S79-S93. doi: 10.3233/JAD-231126. J Alzheimers Dis. 2024. PMID: 39422941 Free PMC article.
Challenges and Opportunities for Consideration of Efavirenz Drug Repurposing for Alzheimer's Disease Therapeutics.
Boyarko B, Podvin S, Greenberg B, Arnold S, Juanes AM, van der Kant R, Goldstein L, Momper JD, Bang A, Silverman J, Feldman HH, Hook V. Boyarko B, et al. Among authors: feldman hh. ACS Pharmacol Transl Sci. 2024 Sep 6;7(10):2924-2935. doi: 10.1021/acsptsci.4c00229. eCollection 2024 Oct 11. ACS Pharmacol Transl Sci. 2024. PMID: 39421657 Review.
2,022 results